

RETHINKING TRIAL DESIGN IN ALS: WHAT ARE THE IDEAL INCLUSION CRITERIA AND OUTCOME MEASURES? A DEBATE

Monday, December 5, 2022, 1:30–2:30pm GMT

Join us for **Rethinking Trial Design in ALS: What Are the Ideal Inclusion Criteria and Outcome Measures? A Debate**, the seventh annual symposium sponsored by Cytokinetics, on **Monday, December 5, 2022, at 1:30–2:30 pm GMT/5:30–6:30 am PST/8:30–9:30 am EST.**

Renowned faculty will review the advantages of traditional and nontraditional outcome measures and eligibility criteria in ALS trial designs.

FACULTY MEMBERS



Jeffrey Rothstein, MD, PhD (CHAIR)
Professor of Neurology and Neuroscience
Director of the Brain Science Institute
Director of the Robert Packard Center
for ALS research
John Hopkins University



Orla Hardiman, MD, FRCPI, FAAN
Academic Unit of Neurology,
Trinity College Dublin
Trinity Biomedical Sciences Institute



Jeremy M. Shefner, MD, PhD
Chief Medical Officer
for Clinical Research
Barrow Neurological Institute

At the end of the program, you will have an opportunity to submit your questions during a live streamed Q&A session. We look forward to seeing you at this lively debate!

If you have any questions, please contact Laura Gschwind at
lgschwind@cytokinetics.com

If you would like to attend this event, please register for the 33rd International Symposium on ALS/MND at: <https://symposium.mndassociation.org/register/>. The event can be accessed via the ALS/MND Symposium meeting link, which will be sent to all registered delegates in early December.

This is not eligible for continuing medical education. This sponsored session is not part of the official ALS MND program. All faculty disclosures will be made at the session.
This is a sponsored session by Cytokinetics, Inc.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.